(MENAFN- Jordan News Agency)
Amman, August 23 (Petra)-- Director General of the Jordan Food and Drug Administration (JFDA), Nizar Muhaidat, called for pharmacological integration between Jordanian and Iraqi pharmaceutical products to enhance drug security in the two countries.
Speaking to a meeting on Tuesday with an Iraqi technical delegation, Muhaidat highlighted the JFDA's journey in drug registration and pricing and inspection of drug manufacturing sites.
He also highlighted the JFDA's supervisory role and its recent qualitative achievements, as well as its role in focusing on the localization of the biopharmaceutical alternatives industry, and the JFDA's continuous support to stimulate the direction of national pharmaceutical factories towards it, providing all possible facilities and accelerating the registration of these items, in a way that contributes to the availability of medicine at more reasonable prices compared to the current prices, achieves savings in the treatment bill and enhances medical tourism.
He expressed the JFDA's readiness to enhance t coordination in the pharmaceutical field, and to strengthen cooperation in the field of training and exchange of expertise.
The delegation from the Iraqi Ministry of Health representing the Registration division's Technical Affairs Department, is chaired by Director of Pharmaceutical Registration, Nofal Abdel Hadi.
Abdel Hadi said there is a periodic review by the Iraqi stakeholders of the work mechanisms adopted by the JFDA and leveraging its experience based on scientific foundations and standards as trusted mechanisms, especially in light of the trend to move from traditional medicines towards generic medicines to bring about a quantum leap in the Iraqi pharmaceutical market and meet its needs.
Abdel Hadi commended the level and efficiency of the Jordanian pharmaceutical industry, and the JFDA's supervisory and supportive role, following the delegation's field visit to the companies of United Pharmaceutical Manufacturing (UPM) and MS Pharma Jordan.
In turn, MS Pharma's Director of Regulatory Affairs, Balsam Al-Ghazi, lauded JFDA's efforts to support the national pharmaceutical industry and its continuous endeavor to strengthen strategic partnerships with the sector, and its constant following-up on all relevant issues, which contributed to supporting its development and expansion.
The visit included field tours in the relevant departments in the Drug Directorate to check on the working mechanisms in place, and presentations about the directorate and its various departments and the working mechanisms in place, and a presentation on the mechanism of drug registration.
MENAFN23082022000117011021ID1104744350
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.